论文部分内容阅读
Elgodipine是一种新合成的第二代双氢吡啶类钙拮抗剂,其扩血管作用较负性肌力作用强100倍,对冠脉的扩张作用最强。本文旨在评价静脉注射elgodipine对冠状动脉疾病病人的冠脉和左室血流动力学的影响。 15例可疑冠状动脉疾病病人,均为窦性心律,无一例有心衰、不稳定心绞痛或急性心肌梗塞。研究前停用一切药物至少48小时。所有病人在测定基础冠脉和左室血流动力学参数后,于10分钟内以每分钟1.5μg/kg的速度静脉注射本品,给药5、10、20和30分钟
Elgodipine is a newly synthesized second generation dihydropyridine calcium antagonist, its vasodilator effect is 100 times stronger than the negative inotropic effect, which has the strongest effect on coronary dilatation. This article aims to evaluate the effects of intravenous elgodipine on coronary and left ventricular hemodynamics in patients with coronary artery disease. 15 cases of suspected coronary artery disease patients, all sinus rhythm, no case of heart failure, unstable angina or acute myocardial infarction. Disable all medication for at least 48 hours prior to study. All patients in the determination of basal coronary artery and left ventricular hemodynamic parameters, within 10 minutes at a rate of 1.5μg / kg per minute intravenous injection of this product, administered 5,10,20 and 30 minutes